Navigation Links
ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
Date:3/3/2008

SACRAMENTO, Calif., March 3 /PRNewswire/ -- ROBODOC, a Curexo Technology Company, and IBM announced today that they have entered into a major patent Cross licensing agreement. The terms of the agreement were not disclosed by either party.

In addition to its current surgical robotics patents, this agreement gives ROBODOC, access to more than 40,000 patents in IBM'S Global Portfolio and particularly, IBM's surgical robotics patents.

Dan Cerutti, IBM's general manager of intellectual property, said, "IBM enjoys a reputation of innovation and invention for technologies related to computer-assisted medicine and surgery. We are pleased to share our innovations in these areas through patent cross licenses, especially with forward-thinking companies such as ROBODOC."

"This agreement provides us with a significant improvement in our freedom of action in the Surgical Robotics and Information Management field. We intend to continue building our own intellectual property portfolio on an on-going basis," commented Dr. Ramesh Trivedi, President and CEO of ROBODOC.

IBM has earned the most U.S. patents for 15 consecutive years. For more information on IBM, please visit http://www.ibm.com.

ROBODOC, a Curexo Technology Company is the United States-based subsidiary of Korea-based Curexo Inc. (KOSDAQ: 060280.KQ). Its main research facility is in the U.S. and it reaches markets throughout the world.

About ROBODOC

ROBODOC, develops, manufactures, and markets a fully automated surgical robotic system for use in orthopaedic surgery. The system includes two components; ORTHODOC, a computer workstation equipped with proprietary software for preoperative surgical planning, and ROBODOC, a computer-controlled surgical robotic assistant for use in hip and knee replacement as well as other orthopaedic procedures. ROBODOC made medical history in 1992 by assisting in a Total Hip Arthroplasty (THA) procedure. Since that time, the ROBODOC system has been used in over 20,000 surgical procedures assisting surgeons around the world. The ROBODOC Surgical Assistance System is currently in its final stage of review and clearance by the FDA.

ROBODOC(R) and ORTHODOC(R) are registered trade marks of Curexo Technology Corporation.
1433 N. Market Blvd., Suite 1, Sacramento, CA 95834

http://www.robodoc.com

Contact: Dr. R.C. Trivedi

President & CEO

ROBODOC(R)

A Curexo Technology Company

916 285 9943 x 527

or

Ms. Sheila Shah

Marketing Communications

ROBODOC(R)

A Curexo Technology Company

916 285 9943 X 510

press@robodoc.com


'/>"/>
SOURCE ROBODOC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
Breaking Biology News(10 mins):